Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
71 hedge funds and large institutions have $131M invested in Stemline Therapeutics, Inc. in 2015 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 32 increasing their positions, 16 reducing their positions, and 8 closing their positions.
625% more call options, than puts
Call options by funds: $384K | Put options by funds: $53K
100% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 16
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
3% more funds holding
Funds holding: 69 → 71 (+2)
21% less capital invested
Capital invested by funds: $166M → $131M (-$35.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$3.29M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$1.17M |
| 3 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$918K |
| 4 |
CLOS
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
|
+$523K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$453K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$6.87M |
| 2 |
SCM
Sio Capital Management
New York
|
-$2.03M |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$1.8M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.45M |
| 5 |
TCM
TimesSquare Capital Management
New York
|
-$1.22M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PPA
76
Parametric Portfolio Associates
Seattle,
Washington
| – | -$238K | -16,457 | Closed |
|
|
MLICM
77
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$185K | -12,765 | Closed |
|
78
AllianceBernstein
Nashville,
Tennessee
| – | -$19K | -1,300 | Closed |
|
79
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$6K | -400 | Closed |
|
STML Hedge Fund Activity: Q2 2015 in Review
71 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q2 2015, worth a combined $131M — down 21% from $166M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new STML positions and 8 closed out — a net gain of 2 holders — while 32 added to existing stakes and 16 trimmed.
The largest buyer was Franklin Resources, adding an estimated $3.29M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $6.87M sold.
- 71 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q2 2015, up from 69 in Q1 2015.
- Funds reported $131M of Stemline Therapeutics, Inc. stock for Q2 2015, down 21% quarter-over-quarter.
- 10 funds opened new Stemline Therapeutics, Inc. positions in Q2 2015 and 8 closed out, a net change of +2 holders.
- The largest Stemline Therapeutics, Inc. buyer in Q2 2015 was Franklin Resources, an estimated $3.29M added.
- The largest Stemline Therapeutics, Inc. seller in Q2 2015 was Avoro Capital Advisors, an estimated $6.87M sold.
Based on aggregated 13F filings for Q2 2015.